Abstract:New Delhi metallo-β-lactamase-1 (NDM-1) poses a threat to public health due to its capability to hydrolyze nearly all β-lactam antibiotics, leaving limited treatment options for NDM-1 positive pathogens. Regrettably, there are presently no effective NDM-1 inhibitors in clinical use. This compels us to seek new compounds to combat multi-drug resistant bacterial infections (MDR). In our study, Zndm19 was identified as a new NDM-1 inhibitor through virtual screening and an NDM-1 enzyme activity inhibition assay. Subsequently, we employed the checkerboard method, time-killing assay, and combined disk test to investigate the synergistic bactericidal efficacy of Zndm19 in combination with meropenem (MEM). Meanwhile, molecular docking and site-directed mutagenesis were conducted to uncover the crucial amino acid residues engaged in Zndm19 binding. Finally, we established a mice peritonitis infection model to assess the synergistic effect of Zndm19 and MEM in vivo. Our findings demonstrated that 16 µg/mL of Zndm19 inhibited NDM-1 activity without affecting NDM-1 expression, restoring the bactericidal activity of MEM against NDM-1-positive Escherichia coli in vitro. Furthermore, MET-67, ASP-124, HIS-189, and HIS-250 amino acid residues constituted the active site of Zndm19 in NDM-1. Importantly, this combination therapy exhibited synergistic anti-infection activity in the mice peritonitis infection model, leading to an approximate 60% increase in survival rates and reduction of tissue bacterial load, effectively combating bacterial infection in vivo. In summary, our research validates that the synthetic novel NDM-1 inhibitor Zndm19 holds promise as a drug to treat drug-resistant bacterial infections, especially those harboring NDM-1.

Design, synthesis and antibacterial activity evaluation of ebselen derivatives in NDM-1 producing bacteria

Ebselen As a Potent Covalent Inhibitor of New Delhi Metallo-Β-lactamase (NDM-1)

1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates

NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings

Discovery of Thiosemicarbazone Derivatives As Effective New Delhi Metallo-Β-lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates.

Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases

Oligopeptides As Full-Length New Delhi Metallo-Β-lactamase-1 (NDM-1) Inhibitors.

Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).

Design of Dipicolinic Acid Derivatives As New Delhi Metallo-Β-lactamase-1 Inhibitors Using a Combined Computational Approach.

Diaryl-substituted thiosemicarbazone: A potent scaffold for the development of New Delhi metallo-β-lactamase-1 inhibitors

Systematic research of H2dedpa derivatives as potent inhibitors of New Delhi Metallo-β-lactamase-1

Structure-based computational study of the hydrolysis of New Delhi metallo-β-lactmase-1

Recent research and development of NDM-1 inhibitors

N-acylhydrazones confer inhibitory efficacy against New Delhi metallo-β-lactamase-1

Discovery of Isatin-Β-methyldithiocarbazate Derivatives As New Delhi Metallo- Β-Lactamase-1 (NDM-1) Inhibitors Against NDM-1 Producing Clinical Isolates

Quinolinyl sulfonamides and sulphonyl esters exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)

Insights from Modeling the 3D Structure of New Delhi Metallo-Β-lactamse and Its Binding Interactions with Antibiotic Drugs.

A Structural View of the Antibiotic Degradation Enzyme NDM-1 from a Superbug

Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition

Molecular Basis Of Ndm-1, A New Antibiotic Resistance Determinant

Thiosemicarbazones exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1)